GMPs, QA & QC
NY Attorney General actions
View from the aisles: Retailer news
NDI draft guidance
Allergies & intolerances
Beauty from within
Blood sugar management
Bone & joint health
Cancer risk reduction
Maternal & infant health
Videos & Audio
Botanicals & Herbals
Dosage forms & delivery formats
Fibers & carbohydrates
Omega-3s & Nutritional oils
Probiotics & prebiotics
Proteins, peptides, amino acids
Vitamins & premixes
Food Jobs - USA
Food Jobs - Europe
Food Jobs - UK
As I stated a week ago in response to the recently released study on resveratrol, the fault here is with the study design and protocol itself, not the resveratrol used in the study. The dosage used in this study was ridiculously low, compared to all earlier studies. In the case of the successful Albert Einstein Medical School study and the more recent Florida Pharmacology School study the dosages were approximately 10 to 20 times this amount. This dosage is consistent with the supplements used in those trials, specifically biotivia transmax and bioforte, which are readily available without a prescription. Using a dosage of only 75mg was tantamount to giving a heart attack victim one aspirin.
In all previous studies on actual type 2 diabetic patients or those suffering impaired glucose tolerance, a sign of impending diabetes, resveratrol was extremely effective in improving glucose tolerance, enhancing metabolic function and blocking the onset of diabetes.
As a cell biologist who has been involved in several human clinical trials of transmax and bioforte resveratrol against diabetes, I can only imagine that this study was designed by a pharmaceutical company to fail intentionally. The pharmas are clearly aware of the potential of resveratrol to cut into their sales of Metformin, a multi-billion dollar earner for the drug companies, and are on a campaign to discredit the compound.
As a researcher I question why the clinicians in this study would select as subjects women who have no issues with glucose tolerance, who were non-obese, and who did not exhibit signs of diabetes. This is equivalent to testing a compound designed to treat cancer on a group of subjects none of whom has cancer. Again, we see a troubling signal of possible pharma involvement.
Posted by James Betz01 November 2012 | 08h40
Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.
We will not publish your email on the site
Back to: Resveratrol study results don’t tell the whole story on benefits: Expert
Probiota Americas 2015
Food Vision USA 2015
Chicago / Conference
Subscribe to our FREE newsletterSUBSCRIBE
Industrial Baking & Snacks
Beverage Technology & Markets
Confectionery & Biscuit Processing
Dairy Processing & Markets
Food Marketing and Retailing
Food & Beverage Development - Europe
Food & Beverage Development - North America
Food and Beverage Processing and Packaging
Food Safety & Quality Control
Supplements & Nutrition - Europe
Breaking News on the Food and Drink Manufacturing Sector
Food, Beverage & Supplement Development - Asia Pacific
Global Trading and Meat Processing
About us | Site map |
© William Reed Business Media SAS 2015, All rights reserved.